Coherus Oncology shares rose 11.4% post-earnings as clinical trial progress and clear data timing on key pipeline assets notably outperformed expectations, supporting confidence in upcoming catalysts and commercial execution.

• Completed target patient accrual for CATALYST-202 first-line hepatocellular carcinoma study of casdozokitug; initial data expected midyear.
• Encouraging prior data showed 38% overall response rate and 17% complete response rate for casdozokitug combo, exceeding historical benchmarks for standard therapy.
• Tagmokitug expansion cohorts progressing well with planned data flow throughout second half of 2026, including multiple tumor types such as head and neck, upper GI, and esophageal cancers.
• Commercial outlook reiterates a progressive ramp to $15 million quarterly in 2026, doubling by 2027, and peaking at $44 million quarterly by 2028.
• Management remains focused on advancing the Treg depletion platform amid evolving competitive dynamics, underscoring pipeline differentiation and future partnering opportunities.